<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02817815</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2015/21</org_study_id>
    <nct_id>NCT02817815</nct_id>
  </id_info>
  <brief_title>Atrial Fibrillation and Characterization of Blood Platelet</brief_title>
  <acronym>FAPS</acronym>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Arterial thromboembolism constitutes a major risk of atrial fibrillation (AF) requiring&#xD;
      antithrombotic therapy. Platelets and microparticles (MPs) are important for hemostasis and&#xD;
      thrombosis, their role during AF is not well known. The principal objective of this study is&#xD;
      to compare morphologic, functional and proteomics characteristics of blood platelet between&#xD;
      AF patients and healthy volunteers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      AF is associated with decreased quality of life and an increased risk of thromboembolic&#xD;
      events. AF is the leading cause of embolic stroke. Identification of factors that may&#xD;
      influence blood coagulability in these patients could better identify therapeutic targets to&#xD;
      optimize anticoagulation. Platelets play a major role in the coagulation process, their study&#xD;
      may provide valuable information. Moreover microparticles from platelet activation are known&#xD;
      to have pathophysiological effects including effects on thrombosis and inhibition of&#xD;
      fibrinolysis. It has also been shown that the microparticles have a role in endothelial&#xD;
      dysfunction and generation of inflammatory condition which are associated with atrial&#xD;
      fibrillation.&#xD;
&#xD;
      Investigators propose in this project, a comparative study between AF patients and healthy&#xD;
      volunteers. Complete characterization of platelet (morphology, platelet function, platelet&#xD;
      proteome) and microparticles levels will be perform. Different site blood sampling (systemic&#xD;
      or cardiac) will be done in patients during their ablation procedure. Patients will be&#xD;
      followed during their hospitalisation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Anticipated">September 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of maximal aggregation level (expressed in aggregation percentage) after ex vivo stimulation by Adenosine Di-Phosphate (ADP), arachidonic acid, ristocetin, collagen and Thrombin Receptor Activating Peptide (TRAP-6mers)</measure>
    <time_frame>Day 1</time_frame>
    <description>Aggregation percentage is measured by the method of light transmission aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of maximal disaggregation level (expressed in disaggregation percentage)</measure>
    <time_frame>Day 1</time_frame>
    <description>Disaggregation percentage is measured by the method of light transmission aggregometry</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measure of platelet volume mean</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the Platelet morphology (shape change)</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of the modification of the membrane receptor expression modification</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Identification of platelet proteins differentially expressed between groups</measure>
    <time_frame>Day 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure of Tissue Factor (TF) dependent microparticles level</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure of fibrinolytic microparticles level</measure>
    <time_frame>Day 1</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">210</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Volunteers</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paroxysmal AF patients in sinus rhythm the day of inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paroxysmal AF patients in atrial fibrillation the day of inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Persistent AF patients in sinus rhythm the day of inclusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Persistent AF patients in atrial fibrillation the day of inclusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Electrocardiogram (ECG)</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling from the cephalic vein</intervention_name>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood sampling from the femoral vein</intervention_name>
    <description>Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>First blood sampling from left atrium</intervention_name>
    <description>Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 3</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
    <arm_group_label>Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Atrial stimulation</intervention_name>
    <description>Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Second blood sampling from left atrium</intervention_name>
    <description>After 20min of continuous AF, a blood sampling from left atrium will be done</description>
    <arm_group_label>Group 2</arm_group_label>
    <arm_group_label>Group 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusion Criteria: valid for all groups&#xD;
&#xD;
               -  Age superior or equal to 18 years old, both genders.&#xD;
&#xD;
               -  Patient affiliated or recipient of a social welfare regimen.&#xD;
&#xD;
               -  Patient's write agreement for study participation after reading information note&#xD;
&#xD;
          -  Inclusion Criteria: specific for groups&#xD;
&#xD;
        Group 1:&#xD;
&#xD;
          -  Volunteers without heart disease.&#xD;
&#xD;
          -  Volunteers who never had AF and not in AF the day of inclusion. Group 2&#xD;
&#xD;
          -  Patient suffering of paroxysmal atrial fibrillation since at least 6 month and&#xD;
             addressed for primo ablation of atrial fibrillation.&#xD;
&#xD;
          -  Patient in sinus rhythm the day of inclusion. Group 3&#xD;
&#xD;
          -  Patient suffering of paroxysmal atrial fibrillation since at least 6 month and&#xD;
             addressed for primo ablation of atrial fibrillation.&#xD;
&#xD;
          -  Patient in atrial fibrillation the day of inclusion Group 4&#xD;
&#xD;
          -  Patient suffering of persistent atrial fibrillation since at least 6 month and&#xD;
             addressed for primo ablation of atrial fibrillation.&#xD;
&#xD;
          -  Patient in sinus rhythm the day of inclusion. Group 5&#xD;
&#xD;
          -  Patient suffering of persistent atrial fibrillation since at least 6 month and&#xD;
             addressed for primo ablation of atrial fibrillation.&#xD;
&#xD;
          -  Patient in atrial fibrillation the day of inclusion&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years.&#xD;
&#xD;
          -  Active smoker (&gt; 10 cigarettes/days)&#xD;
&#xD;
          -  Pregnant woman or breastfeeding women or not receiving effective contraception.&#xD;
&#xD;
          -  Volunteer participating in another interventional study requiring taking drug.&#xD;
&#xD;
          -  Volunteer having taken antinflammatory, platelet anti-aggregant or calcium-channel&#xD;
             blocker drugs within 8 days prior to inclusion&#xD;
&#xD;
          -  Valvular heart diseases.&#xD;
&#xD;
          -  Chronic inflammatory diseases.&#xD;
&#xD;
          -  Cardiovascular event or stroke within 3 month prior to inclusion&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Chronic hepatic or renal diseases.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Frédéric SACHER, Dr</last_name>
    <phone>(0)5 57 65 64 71</phone>
    <phone_ext>+33</phone_ext>
    <email>frederic.sacher@chu-bordeaux.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion LEFEVRE</last_name>
    <phone>(0)5 57 62 30 91</phone>
    <phone_ext>+33</phone_ext>
    <email>marion.lefevre@chu-bordeaux.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Electrophysiologie et de stimulation cardiaque / LIRYC - Hôpital Cardiologique du Haut Lévêque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Frédéric SACHER, Dr</last_name>
      <phone>0()5 57 65 64 71</phone>
      <phone_ext>+33</phone_ext>
      <email>frederic.sacher@chu-bordeaux.fr</email>
    </contact>
    <contact_backup>
      <last_name>Marion LEFEVRE</last_name>
      <phone>(0)5 57 62 30 91</phone>
      <phone_ext>+33</phone_ext>
      <email>marion.lefevre@chu-bordeaux.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Frédéric SACHER, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mélèze HOCINI, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre JAIS, Pr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nicolas DERVAL, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud DENIS, Dr</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <study_first_submitted>June 22, 2016</study_first_submitted>
  <study_first_submitted_qc>June 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 29, 2016</study_first_posted>
  <last_update_submitted>June 24, 2016</last_update_submitted>
  <last_update_submitted_qc>June 24, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial fibrillation, blood platelet</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

